Home
  • Clinical Trials
  • Partnerships
  • Contact Us
  • News & Resources
  • Careers
  • About Us
    • Management Team
    • Board of Directors
    • Scientific and Clinical Advisory Boards
    • Commercial Advisory Board
  • Our Focus
    • Infectious Disease
    • Oncology
  • Our Product
  • Our Pipeline
    • Prophylactic
    • Therapeutic
    • Clinical Trials
    • Publications
    • Early/Expanded Access Policy
  • Our Science
  • Investors
    • Press Releases
    • Events and Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • About Us
    • Management Team
    • Board of Directors
    • Scientific and Clinical Advisory Boards
    • Commercial Advisory Board
  • Our Focus
    • Infectious Diseases
    • Oncology
  • Our Pipeline
    • Prophylactic
    • Therapeutic
    • Clinical Trials
    • Publications
    • Early/Expanded Access Policy
  • Our Product
  • Our Science and Technology
  • News and Resources
    • News
    • Posters
    • Publications
    • Videos
  • Investors
    • Press Releases
    • Company Information
    • Corporate Governance
    • Events and Presentations
    • SEC Filings
    • Stock Information
  • Careers
  • Partnerships
  • Contact Us
Search our website

Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine

September 1, 2014 |

Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine
Vaccine
September 2014

View More

May 15, 2023

VBI Vaccines Reports First Quarter 2023 Financial Results


April 25, 2023

VBI Vaccines Appoints Vaughn Himes to Board of Directors


April 4, 2023

VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split


March 13, 2023

VBI Vaccines Reports Full Year 2022 Financial Results


Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top
Navigate
  • About Us
  • Our Focus
  • Our Science and Technology
  • Our Pipeline
  • Investors
  • Clinical Trials
  • Contact Us
About Us
  • Management Team
  • Board of Directors
  • Scientific and Clinical Advisory Boards
  • Commercial Advisory Board
  • Partnerships
  • News and Resources
  • Careers
Connect With Us
  • Twitter Icon
  • Facebook Icon
  • YouTube Icon
  • LinkedIn Icon
VBI Logo Home

© 2023 VBI Vaccines Inc. All rights reserved.

  • Privacy Policy
  • Cookies Policy
  • Terms of Use
  • Site Map
  • Contact Us